{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:24:02Z","timestamp":1764937442760,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jaip.2022.07.029","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T02:01:14Z","timestamp":1660010474000},"page":"3026-3028.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0360-1237","authenticated-orcid":false,"given":"Paola","family":"Faverio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Monzio Compagnoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Della Zoppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Bonaiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Pesci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Corrao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.07.029_bib1","article-title":"Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2022.07.029_bib2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1080\/17476348.2016.1205490","article-title":"The path to personalized medicine in asthma","volume":"10","author":"Bagnasco","year":"2016","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jaip.2022.07.029_bib3","article-title":"Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma","volume":"55","author":"D\u2019Ancona","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2022.07.029_bib4","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1111\/all.14737","article-title":"Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma","volume":"76","author":"D\u2019Ancona","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.07.029_bib5","doi-asserted-by":"crossref","first-page":"00465","DOI":"10.1183\/23120541.00465-2021","article-title":"Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma","volume":"7","author":"Noorduyn","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2022.07.029_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pupt.2018.12.003","article-title":"Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life","volume":"54","author":"Lombardi","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaip.2022.07.029_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100509","article-title":"Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life","volume":"14","author":"Bagnasco","year":"2021","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2022.07.029_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12931-021-01758-0","article-title":"Real-life cost-effectiveness of benralizumab in patients with severe asthma","volume":"22","author":"Padilla-Galo","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2022.07.029_bib9","first-page":"877","article-title":"Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden","volume":"23","author":"Andersson","year":"2020","journal-title":"J\u00a0Med Econ"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822007991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822007991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:34:21Z","timestamp":1761975261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822007991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2213219822007991"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.07.029","relation":{},"ISSN":["2213-2198"],"issn-type":[{"type":"print","value":"2213-2198"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}